DRG Market Assessment 보고서
질환 개요 및 예측, 역학 인텔리전스, 바이오시밀러 인텔리전스, China In-depth 등 폭넓은 시장 인텔리전스를 확인해 보세요.
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Asia Pacific
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Europe
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Americas
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Emerging Markets
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Mature Markets
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2025
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Axial Spondyloarthritis – Unmet Need – Unmet Need – Nonradiographic Axial Spondyloarthritis (US/EU)
TNF-alpha inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Simponi, and UCB’s Cimzia, are approved for the treatment of nonradiographic axial…
